News | March 24, 2025
Marksans Pharma’s manufacturing facility at Verna, Goa approved by Australian TG
The products will be manufactured in Goa India and marketed & distributed in Australian markets
The products will be manufactured in Goa India and marketed & distributed in Australian markets
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Subscribe To Our Newsletter & Stay Updated
